Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% response rate for the ...
Efficacy and safety of FCN-159, a MEK1/2 inhibitor in pediatric participants with neurofibromatosis type 1: Results from a phase 2 trial. Alectinib in pediatric patients with solid or CNS tumors ...
Prediction of Treatment Efficacy in Locally Advanced Rectal Cancer Using a Clinical and Magnetic Resonance Imaging–Based Radiomics-Immunological Model for Total Neoadjuvant Therapy Fifty patients were ...
LTI-03 in idiopathic pulmonary fibrosis (IPF)First patient randomized in the United KingdomClinical trial sites now actively ...
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a significant milestone in its pancreatic cancer development program, with enrollment of the final subject, barring ...
SHELTON, CT / ACCESS Newswire / June 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides ...
Construction on Phase 1 of Ralph Wilson Park will soon be wrapping up, with remaining work that includes lawn installation, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results